The oligosaccharide antibiotic avilamycin A is composed of a polyketide-derived dichloroisoeverninic acid moiety attached to a heptasaccharide chain consisting of six hexoses and one unusual pentose moiety. We describe the generation of mutant strains of the avilamycin producer defective in different sugar biosynthetic genes. Inactivation of two genes (aviD and aviE2) resulted in the breakdown of the avilamycin biosynthesis. In contrast, avilamycin production was not influenced in an aviP mutant. Inactivation of aviGT4 resulted in a mutant that accumulated a novel avilamycin derivative lacking the terminal eurekanate residue. Finally, AviE2 was expressed in Escherichia coli and the gene product was characterized biochemically. AviE2 was shown to convert UDP-D-glucuronic acid to UDP-D-xylose, indicating that the pentose residue of avilamycin A is derived from D-glucose and not from D-ribose. Here we report a UDP-D-glucuronic acid decarboxylase in actinomycetes.
Introduction
Avilamycins are oligosaccharide antibiotics isolated from Streptomyces viridochromogenes Tü 57 (S. viridochromogenes Tü 57) [1] (Figure 1 ). Avilamycin A, the main compound produced by the strain was shown to be active against many Gram-positive bacteria, including emerging problem organisms such as vancomycinresistant enterococci, methicillin-resistant staphylococci, and penicillin-resistant pneumococci [2] . Evernimicin (Ziracin), which is structurally very similar to avilamycin, was under investigation for approval by ScheringPlough. Due to side effects and its poor water solubility, further development was stopped in 2000 [3] . Evernimicin and avilamycin were shown to inhibit protein biosynthesis by binding to the 50S ribosomal subunit of the bacterial ribosomes [4] [5] [6] . It was suggested that they interact with the ribosomal A-site and interfere with initiation factor IF2 and tRNA binding.
Recently, we reported the sequence of the complete biosynthetic gene cluster for avilamycin A [7] . Based on sequence similarities of the deduced proteins to enzymes of known functions, putative biosynthetic pathways to each sugar were proposed. Gene disruption experiments with putative methyltransferase genes [2] have led to new avilamycins with enhanced water solubility (named gavibamycins) ( Figure 1 ) and after deletion of aviB1 and aviO2 an avilamycin derivative (gavibamycin O) was obtained lacking the acetyl residue at position C-4 of the eurekanate moiety of avilamycin A [8] .
It is most likely that the biosynthesis of avilamycin A starts with the formation of the unusual disaccharide consisting of the pentose L-lyxose and the hexose D-mannose. The attachment of the progenitor of eurekanate to the C-4 position is a further plausible step toward the formation of the heptasaccharide side chain. However, insights regarding early steps in the biosynthesis of avilamycin A are sparse.
Our recent elucidation of the avilamycin gene locus revealed several deoxy sugar biosynthetic genes and four glycosyltransferase genes. Based on sequence homologies AviD, a putative dNDP-glucose synthetase, was discussed to be the entrance enzyme of the D-olivose and 2-deoxy-D-evalose pathway. AviP, a putative phosphatase, was thought to be the first enzyme of the pathway leading to L-lyxose and AviE2, a putative 4,6-dehydratase, leading to eurekanate.
In order to gain insights into the biosynthesis of the avilamycin molecule, we now report classical feeding experiments, the generation of four mutants of the avilamycin producer with deletion in different sugar biosynthetic and glycosyltransferase genes and the overexpression of aviE2 in E. coli.
Our results indicate that L-lyxose derives from D-glucose by decarboxylation and that AviGT4 is a glycosyltransferase involved in the formation of the orthoester linkage between L-lyxose and the eurekanate residue.
Results and Discussion
Feeding of Labeled D-Glucose Labeled glucose (U- 13 C glucose, 1-13 C glucose) was added to the culture medium inoculated with S. viridochromogenes Tü 57. Avilamycin A was isolated by reverse phase chromatography and preparative high pressure liquid chromatography-mass spectrometry (HPLC-MS). In the nuclear magnetic resonance (NMR) spectra of the labeled compound obtained by feeding 1-13 C glucose (Figure 2a) , the signal volumes of all carbons in the C-1 positions are identical (within error limits of 11%) and w8-fold larger than the signal volumes of carbons at other positions. This increased occurrence of 13 C at the C-1 positions indicates usage of D-glucose as a precursor for all components, which was in contrast to the assumption that ribose-5-phosphate is the precursor of L-lyxose [7] .
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The NMR analysis of the U- 13 C glucose feeding experiment ( Figure 2b ) allowed to identify D-glucose as the source of the methyl group at position C-5 of the eurekanate residue. The signal of 35 (see Figure 1 for nomenclature) is representative for a methyl group derived directly from D-glucose, whereas position 27 is an example for a CH 3 -group attached to the sugar ring at a later stage of the biosynthesis. (This has been shown by 13 C-labeled L-methionine feeding experiments described in [7] .) Integration of a variety of signals (among them the ones of positions 35 and 58) showed that the average degree of 13 C-labeling was w20%, whereas position 27 was labeled to only w8%, indicating that position 58 is derived directly from D-glucose. The shapes of the signals prove this assumption. The signals of 35 and 58 show small, uncoupled singlets and large doublets caused by the 1 J 13C,13C couplings to the adjacent carbons in the sugar rings (positions 33 and 57, respectively). Thus, a labeled methyl group has a very high probability (>90%) of being connected to a 13 C-atom. Because of the average degree of 13 Clabeling (w20%), this is possible only if the complete C 6 scaffold of the U- 13 C glucose, including the methyl group, is inserted as a whole during biosynthesis. On the other hand, the signal of position 27 shows a large singlet and a small doublet. For this position, therefore, the probability of being connected to a 13 C in the ring (at position 24) is in the range of the average degree of labeling, confirming the subsequent addition of the methyl group to the U-13 C glucose scaffold. Because evernimicin, another orthosomycin antibiotic, lacks a methyl group at position C-5 of eurekanate, different biosynthetic pathways to both antibiotics have to be discussed.
Generation of S. viridochromogenes Tü 57DaviD, S. viridochromogenes GW4DaviP, S. viridochromogenes GW4DaviE2, and S. viridochromogenes GW4DaviGT4 For generation of mutants, gene inactivation experiments were carried out. As hosts we used S. viridochromogenes Tü 57 and S. viridochromogenes GW4, a mutant lacking the methyltransferase gene aviG4 [7] . Plasmids were constructed as described in Experimental Procedures, allowing the replacement of the wild-type gene by a mutated allele in S. viridochromogenes Tü 57. The deletions within the genes were confirmed by polymerase chain reaction (PCR) (aviD, aviP, aviE2, aviGT4) and by Southern hybridization (aviD, aviP, aviE2). PCR fragments obtained from double crossover mutants (S. viridochromogenes Tü 57DaviD, S. viridochromogenes GW4DaviP, S. viridochromogenes GW4DaviE2, Figure 1 for nomenclature). The signal of 35 is representative for a methyl group derived directly from D-glucose whereas position 27 is an example for a CH 3 -group attached to the sugar ring at a later stage of the biosynthesis [7] . and S. viridochromogenes GW4DaviGT4) using primers aviD-F2/aviD-R2, aviP-A/aviP-B, aviE2P-F/aviE2P-R, and aviGT4-F2/aviGT4-R2, respectively, could not be digested by SmaI, NotI, BamHI, and NotI, respectively (Figure 3) , whereas the PCR fragments obtained from S. viridochromogenes Tü 57 and S. viridochromogenes GW4 could be digested by the enzymes. To determine clearly that the mutation event affected only the desired genes and not other genes, aviE2 and aviGT4 were ligated behind the ermE* promoter of pSET-1cerm and were introduced by protoplast transformation into the corresponding mutants. Complementation of S. viridochromogenes Tü 57DaviD was achieved by expression of a 5 kb fragment containing aviD behind the native promoter. Avilamycin (gavibamycin) production was restored in each case.
Isolation and Identification of Avilamycin Derivatives S. viridochromogenes Tü 57, S. viridochromogenes GW4, S. viridochromogenes Tü 57DaviD, S. viridochromogenes GW4DaviP, S. viridochromogenes GW4DaviE2 and S. viridochromogenes GW4DaviGT4 were grown under the conditions described in Experimental Procedures. Extracts were analyzed by thin-layer chromatography (TLC), HPLC-UV/Vis, and HPLC-ESI (electrospray ionization)-MS. Avilamycin A and C were detected in S. viridochromogenes Tü 57 (wild-type strain), gavibamycins A1 and A3 were detected in S. viridochromogenes GW4 and S. viridochromogenes GW4DaviP. No avilamycin derivative could be observed in S. viridochromogenes Tü 57DaviD and in S. viridochromogenes GW4DaviE2. The HPLC-ESI-MS analysis of the mutant S. viridochromogenes GW4DaviGT4 revealed that none of the gavibamycins typically found in S. viridochromogenes GW4 were produced. Instead, a novel compound with the typical UV/Vis spectrum of the gavibamycin chromophore was identified. Its molecular ion with m/z
[M-H]
2 displayed the diagnostic isotope pattern distinctive for the double-chlorinated gavibamycins ( Figure 4) . Hence, the compound was very likely a gavibamycin derivative, referred to as gavibamycin P1. The mass difference of 198 amu compared to gavibamycin
) produced by S. viridochromogenes GW4 indicated a lacking eurekanate moiety, the terminal residue of the oligosaccharide chain ( Figure  4 ). To corroborate this structure, a comparative fragmentation analysis with an atmospheric pressure chemical ionization (APCI) source was carried out with gavibamycin A1 serving as reference. For this purpose, gavibamycins P1 and A1 were purified from S. viridochromogenes GW4DaviGT4 and S. viridochromogenes GW4, respectively. Subsequent fragmentation analysis revealed an analogous fragmentation pattern for both compounds in the negative ionization mode (Figure 4 ). Two groups of fragments could be observed. First, fragments with the isotope profile of the chlorinated orsellinic acid and equal mass between gavibamycin P1 ESI-MS analysis yields the deprotonated molecule with m/z 1387 and m/z 1189, respectively. In both cases, the diagnostic isotope pattern reflects the presence of the double-chlorinated orsellinic acid. APCI-MS analysis yields an analogous fragmentation pattern of both compounds. The fragments labeled with an asterisk display the isotope pattern of the orsellinic acid. All further fragments differ in 198 amu between gavibamycin A1 and P1, representing the lacking terminal eurekanate residue in gavibamycin P1. and A1. Second, fragments that differed in 198 amu from those derived from gavibamycin P1 displaying the lower mass. These fragments represent a terminally shortened oligosaccharide chain and therefore can plausibly explain the structure of a gavibamycin lacking the eurekanate residue (Figure 4) .
Although it was expected that the aviD mutant would not produce any avilamycin derivative, production of avilamycins by the aviP mutant and nonproduction by the aviE2 mutant were surprising results. We concluded that AviP is not involved in the formation of the L-lyxose moiety and that AviE2 is not an NDP-glucose 4,6-dehydratase involved in the eurekanate biosynthesis.
AviGT4 Is Involved in the Formation of the Linkage between L-Lyxose and Eurekanate
Because our data show that the derivative gavibamycin P1 produced by S. viridochromogenes GW4DaviGT4 lacks the terminal eurekanate moiety and because AviGT4 matches GTs that are involved in cell envelope and lipopolysaccharide biosynthesis, we conclude that AviGT4 is essential for the transfer of the eurekanate residue to the L-lyxose moiety. For now, we cannot predict whether AviGT4 is responsible for the formation of a ''simple'' glycosidic bond or whether it catalyzes the entire formation of the orthoester. Results of the aviGT4 inactivation experiments revealed that the disaccharide L-lyxose-eurekanate is not the starter molecule for avilamycin A biosynthesis. It now seems likely that the avilamycin biosynthesis begins within the formation of the
AviE2, a Decarboxylase as Key Enzyme for the Generation of L-Lyxose during Avilamycin A Biosynthesis Results of the knockout experiments prompted us to perform a careful BLAST analysis of the encoded AviE2. AviE2 is homologous to other enzymes that oxidize the C-4 position of certain UDP-sugars, such as UDP-galactose epimerase [9] , dTDP-glucose-4,6-dehydratase [10] , and eukaryotic UDP-glucuronic acid (UDP-GlcA) decarboxylases [11, 12] , all belonging to the short chain dehydrogenase/reductase superfamily [13, 14] . This group of proteins is characterized by high structural similarity and the presence of specific sequence motifs despite low overall sequence identity [15] [14] . The sequence YXXXK, together with a conserved T/S residue, is responsible for the NAD + dependent oxidation of a sugar hydroxyl group at position C-4 in UDP-sugars, and these motifs are also present in AviE2, represented by residues T 134 and Y 163 DEAK 167 . Serine and lysine are suggested to activate tyrosine to abstract the C-4 proton to yield a nucleotide-4-keto sugar intermediate [16] . A glutamate D 164 (prevents ring flipping) and an arginine R 318 (responsible for decarboxylation) are strictly conserved in UDPGlcA decarboxylases [17] . Both are existing in AviE2. An aspartate, which is conserved in 4,6-dehydratases [18] , is occupied by a serine (S 135 ) in AviE2. This serine has been shown to be involved in the decarboxylation process of UDP-decarboxylases [17] . To prove the function of AviE2, the corresponding gene was overexpressed in E. coli as His-tag fusion protein. Subsequent AviE2 characterization revealed this protein to be a UDP-GlcAdecarboxylase ( Figure 5 ). The product of the AviE2 reaction was identified as UDP-D-xylose by HPLC-MS ( Figure 6 ) and by NMR analysis. The chemical shifts measured in the 1D-spectra were in very good accordance with the literature [19] and, moreover, have been verified using the 2D-experiments described in Experimental Procedures. The 3 J H1,H2 coupling constant of 3-3.5 Hz (lit.: 3.5 Hz) confirmed the a-anomeric configuration of the UDP-pentose. The identification as UDP-D-xylose was based on the measured 3 J H3,H4 coupling constant of 9 6 0.5 Hz (lit.:
3 J H3,H4 (xylose) = 8.9 Hz; 3 J H3,H4 (arabinose) = 3.4 Hz).
Replacement of the UDP-GlcA substrate with UDPGlc or NAD + with NADP + yielded no product, indicating specificity of the reaction for UDP-GlcA and NAD + . The activity obeyed Michaelis-Menten kinetics with a K m of w1.2 mM for UDP-GlcA, which is reasonable for this type of enzyme [14, 15] . The dexcarboxylation of UDP-D-GlcA to UDP-D-xylose is a common enzymatic step in the formation of pentoses for the primary metabolism [19, 20] , but has never been described as enzymatic step in the formation of pentoses for the secondary metabolism in actinomycetes. The identification of AviE2 as a UDP-GlcA decarboxylase indicates that the formation of avilamycin A starts with the formation of UDP-L-lyxose from UDP-Dglucose. Thorson and coworkers proposed a similar biosynthetic pathway to the deoxypentose moieties of enediyne antitumor antibiotics. They found a UDP-glucose dehydrogenase encoding gene (calS8) in the calicheamicin gene cluster responsible for the conversion of UDP-D-glucose to UDP-D-GlcA and also a gene encoding a putative decarboxylating enzyme (CalS9) [21] . Interestingly, no UDP-glucose dehydrogenase encoding gene candidate has been detected in the avilamycin gene cluster so far. The conversion of UDP-D-xylose to UDP-L-lyxose requires two additional epimerization steps ( Figure 7 ). There are candidates in the avilamycin gene cluster (aviQ1, aviQ2, aviQ3) that might be involved in these biosynthetic steps.
Significance
To our knowledge, this is the first report on avilamycin A biosynthetic enzymes involved in the formation of the hexasaccharide biosynthesis. Our data show that AviGT4 is involved in the formation of the unusual orthoester linkage between the eurekanate portion and L-lyxose. Gene inactivation as well as gene expression and biochemical experiments indicate that AviE2 is involved in the decarboxylation of UDPGlcA to form UDP-D-xylose. Based on the increasing level of interest in new antibiotics, biosynthetic studies are of importance and will pave the way for the formation of novel derivatives in the future.
Experimental Procedures
Feeding Experiments S. viridochromogenes Tü 57 was grown on 1% malt extract, 0.4% yeast extract, and 0.4% glucose (pH adjusted to 7.5) [HA-medium] at 37ºC and 180 rpm. For avilamycin production, S. viridochromogenes Tü 57 was grown at 28ºC in SG medium containing 2% glucose, 1% soy peptone, 0.1% CaCO 3 , 20 mM L-valin, and 1 ml of 0.1% CoCl 2 (pH adjusted to 7.2). Then 100 mg/l of the U-13 C -glucose or 1-13 C -glucose was added after 24 and 48 hr. The avilamycins were isolated after 72 hr of cultivation and purified as described previously [2] . After purification, the substances were analyzed by 13 C-NMR.
Bacterial Strains, Plasmids, and Culture Conditions DNA manipulation was carried out using E. coli XL-1 Blue MRF 0 (Stratagene) as the host strain. Before transforming S. viridochromogenes strains, plasmids were propagated in E. coli ET 12567 (dam 2 , dcm 2 , hsdS, Cm R ) [22, 23 ] to obtain unmethylated DNA. E. coli strains were grown on Luria-Bertani (LB) agar or liquid medium containing the appropriate antibiotic. pBluescript SK 2 (pBSK 2 ) and pBC-SK 2 were from Stratagene; pUC19 was from New England Biolabs. Plasmid pSP1 [24] , conferring erythromycin resistance, was a kind gift of Dr. S. Pelzer, and pSET152 [25] , conferring apramycin resistance, was obtained from Eli Lilly & Co. The construction of pSET-1cerm has been described [26] .
General Genetic Manipulation, PCR, and Sequence Analysis Routine methods were performed as described [27] . Isolation of E. coli plasmid DNA, DNA restriction, DNA modification, and Southern hybridization were performed following the manufacturer's directions (Amersham Biosciences, Roche Diagnostics, Promega, Stratagene). Streptomyces protoplast formation, transformation, and protoplast regeneration were performed as described [28] . PCR was carried out using a GeneAmp PCR System 9700 (Applied Biosystems). Oligonucleotide primers from Qiagen are listed in the Supplemental Data. Computer-aided sequence analysis was done with the DNAsis software package (version 2.1, 1995; Hitachi Software Engineering). Database searches were performed with the BLAST 2.0 program [29] on the server of the National Center for Biotechnology Information, Bethesda, MD.
Construction of Gene Inactivation Plasmids aviE2
AviE2, located on a 2.6 kb EcoRI/SacI fragment, was ligated into pBCSK 2 to generate plasmid pBC-aviE2. A unique BamHI restriction site was altered by BamHI restriction and subsequent treatment with T4 DNA polymerase and religation. DNA sequencing showed that treatment with T4 DNA polymerase led to a 36 bp deletion in aviE2. After restriction with EcoRI and SacI, the insert was transferred to plasmid pSP1 to generate pSP-aviE2. aviP A 3.7 kb SacI fragment containing aviP was ligated in pBSK 2 . A unique BsmI restriction site was used for modification by restriction with BsmI, treatment with T4 DNA polymerase and subsequent religation of the plasmid. DNA sequencing revealed the deletion of 25 bp in aviP.
After restriction with SacI and XbaI, the insert was ligated in plasmid pSP1. By restriction with NotI and following religation, the insert was shortened to 1.8 kb. The resulting construct was named pSP-aviP. aviD A 2.85 kb section including the entire reading frame of aviD was amplified by PCR. Primers aviD-F1 and aviD-R1, which introduced restriction sites for HindIII and BamHI, were used. This PCR fragment was cloned into pUC19 to give pUC19/aviD. By restriction with SacII and ligation of the remaining plasmid, a 291 bp fragment was deleted out of the gene aviD. The intended alteration was checked by DNA sequencing using the primer aviD-BS1. The altered 2.57 kb insert of pUC19/aviD-S was excised by HindIII and EcoRI and was ligated in the PstI and EcoRI sites of pSP1 after generation of blunt ends by the Klenow enzyme leading to the final inactivation plasmid pSP1/aviD-S. aviGT4 A region of 2.8 kb containing aviGT4 was amplified from chromosomal DNA using primers aviGT4-F1 and aviGT4-R1. The PCR product was ligated into the EcoRI and XbaI sites of pUC19. To shift the reading frame of aviGT4, the plasmid was linearized by digestion of a singular NotI site internal to aviGT4 and treated with T4-polymerase to blunt the sticky ends. After religation, the intended alteration (correct fill-in) was confirmed by DNA sequencing. Finally, the EcoRI-XbaI-insert was cloned into pSP1, yielding pSP1_aviGT4i.
Construction of Complementation Plasmids for aviE2, aviGT4, and aviD aviE2 For generation of the plasmid pSETerm-aviE2 used to complement the decarboxylase mutant, aviE2 was amplified by PCR. As suitable restriction sites, EcoRI and XbaI were introduced upstream and downstream of the gene using oligonucleotide primers aviE2F and aviE2R. Plasmid pSET-1cerm was digested with MunI and XbaI to remove urdGT1c, and aviE2 was cloned behind the ermE* promoter after restriction of the PCR product using EcoRI and XbaI. The resulting complementation plasmid was named pSETerm-aviE2. aviD A 5 kb fragment including aviD was cut out of a 7.7 kb SacI fragment (P2S11) using BamHI and EcoRI. The fragment was cloned into the BamHI and EcoRI site of pSET152 to yield complementation construct pSET152/aviD. aviGT4 A 2.8 kb fragment containing aviGT4 was amplified from chromosomal DNA using primers aviGT4-F1 and aviGT4-R1. The PCR product was digested by EcoRI/XbaI and ligated into pSET-1cerm restricted by MunI/XbaI to yield pSETermE-aviGT4.
Expression and Purification of AviE2
The aviE2 gene was PCR-amplified using NcoI-modified primer E2A and EcoRI-modified primer E2B and subcloned into the vector pRSETb (Invitrogen) to form plasmid pRSET-E2. DNA sequence of the coding region was confirmed by sequencing (4base lab).
For purification of expressed protein, E. coli strain BL21 (DE3) pLysS cells (Stratagene), carrying either pRSET-E2 with aviE2 or the pRSETb vector alone, were grown in NZCYM medium containing 50 mg/ml carbenicillin and 30 mg/ml chloramphenicol to OD 600 = 0.6. Protein expression was induced for 4 hr at 28ºC with 1mM isopropylb-D-thiogalactopyranoside. Cells were harvested by centrifugation and stored at 220ºC. The cell pellet from 100 ml culture was resuspended in 4 ml lysis buffer (NaH 2 PO 4 50 mM, NaCl 300 mM, imidazol 10 mM) containing 1 mg/ml lysozyme and stored on ice for 30 min. After centrifugation, the supernatant fraction was used for purification.
Protein was bound to Ni-NTA agarose (Qiagen) and loaded on a column. The column was washed twice with washing buffer containing 20 mM imidazol. The protein was eluted with elution buffer containing 250 mM imidazol. SDS-PAGE of the starting material and the eluted fraction is shown in Figure 7 .
Decarboxylase Assay
Standard analytical enzyme assays (200 ml) were performed at 23ºC for 60 min. One incubation mixture contained 40 mM Tris-HCl (pH 7,4), 1mM NAD + , 1 mM UDP-GlcA and 1.3 mg/ml AviE2. Reactions were stopped by the addition of 200 ml of phenol-chloroform, vortex-mixed and subjected to centrifugation (14,000 rpm, 5 min, room temperature). The aqueous phase was reserved, and the organic phase was reextracted with 160 ml H 2 O. The two aqueous phases were pooled and further purification was achieved by HPLC (Agilent 1100) on a 150 3 4.6 mm quaternary amine-silica gel ion exchange column (Zorbax 5 mm SAX, Agilent) run at 1.5 ml/ min. After injection, the column was washed for 5 min with mobile phase A (5% glacial acetic acid in water) and then eluted with a 18 min linear gradient from 12% to 45% with solvent B (0.5 M NH 4 HCO 3 , pH 7 in water) and water. The LC eluent was split (Agilent splitter) 1:50 with water and transferred to a mass spectrometer (Agilent). The make-up pump was set to 0.5 ml/min. The mass spectrometer consisted of an electrospray chamber and a quadrupole detector. For NMR analysis, 12.9 mg UDP-GlcA was used in a 10 ml incubation mixture. After 8 hr, the product was purified by HPLC-MS, dissolved in water, relyophilized several times, exchanged twice with 99% D 2 O, and then subjected to NMR analysis.
ESI-and APCI-MS Analysis
Mass spectrometry of purified gavibamycins A1 and P1 was performed on an Agilent 1100 series system optionally equipped with either an ESI or APCI chamber and a quadrupole detector. Samples were dissolved in 100% CH 3 CN and directly applied to the ionization chamber with a 90:10 (CH 3 CN:H 2 O) eluent at a flow rate of 0.7 ml/min.
To determine the [M-H]
2 molecular ions, ESI spectrometry was carried out using chamber settings as follows: drying gas flow, 12 l/min (nitrogen); drying gas temperature, 350ºC; nebulize pressure, 50 psig; capillary voltage (negative), 3kV. Samples were analyzed in the negative ionization mode with a mass range set to 400-1400 Da. For fragmentation analyses, APCI spectrometry was carried out under the following chamber conditions: drying gas flow, 12 l/min (nitrogen); drying gas temperature, 350ºC; nebulize pressure, 50 psig; vaporizer temperature, 450ºC; capillary voltage (negative), 3kV; corona current, 25 mA. Samples were analyzed in the negative ionization mode with a mass range set to 180-1450 Da.
NMR Analysis
The experiments were recorded in DMSO-d 6 at 295 K on Bruker DMX spectrometers (600 and 750 MHz) using 5 mm Shigemi tubes: 1 H-1D, 13 C-1D, COSY [30] , TOCSY [31] [32] [33] , ROESY [34] (mixing time: 150 ms), HSQC [35] , HMBC [36] , and HMQC-COSY [37] . All spectra were assigned using the program SPARKY [38] .
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